166 related articles for article (PubMed ID: 30143818)
1. Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain.
Deza G; Notario J; Ferran M; Beltrán E; Almirall M; Alcalá R; Ruiz-Carrascosa JC; Sánchez R; Pérez S; García-Vivar ML; Galíndez E; Mora M; Rodríguez J; Gallardo F
Rheumatol Int; 2018 Nov; 38(11):2037-2043. PubMed ID: 30143818
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.
Behrens F; Meier L; Prinz JC; Jobst J; Lippe R; Löschmann PA; Lorenz HM
J Rheumatol; 2018 Jun; 45(6):802-810. PubMed ID: 29606665
[TBL] [Abstract][Full Text] [Related]
3. Etanercept in psoriatic arthritis.
Spadaro A; Lubrano E; Ferrara N; Scarpa R
J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
[TBL] [Abstract][Full Text] [Related]
4. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Schmalzing M; Kellner H; Askari A; De Toro Santos J; Vazquez Perez-Coleman JC; Foti R; Jeka S; Haraoui B; Allanore Y; Peichl P; Oehri M; Rahman M; Furlan F; Romero E; Hachaichi S; Both C; Brueckmann I; Sheeran T
Adv Ther; 2024 Jan; 41(1):315-330. PubMed ID: 37950790
[TBL] [Abstract][Full Text] [Related]
6. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
Iannone F; Lopriore S; Bucci R; Lopalco G; Chialà A; Cantarini L; Lapadula G
J Rheumatol; 2016 May; 43(5):911-7. PubMed ID: 26980583
[TBL] [Abstract][Full Text] [Related]
7. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials.
Combe B; Behrens F; McHugh N; Brock F; Kerkmann U; Kola B; Gallo G
J Rheumatol; 2016 Jun; 43(6):1063-7. PubMed ID: 27134249
[TBL] [Abstract][Full Text] [Related]
9. Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study).
de Vlam K; Boone C; The Prove Study Group A
Clin Exp Rheumatol; 2015; 33(5):624-31. PubMed ID: 26212872
[TBL] [Abstract][Full Text] [Related]
10. Etanercept in the treatment of psoriatic arthritis.
Puig L; López-Ferrer A; Laiz A
Actas Dermosifiliogr; 2015 May; 106(4):252-9. PubMed ID: 25455504
[TBL] [Abstract][Full Text] [Related]
11. Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients.
de Stefano R; Frati E; de Quattro D; de Stefano L
J Clin Rheumatol; 2018 Apr; 24(3):127-131. PubMed ID: 29293113
[TBL] [Abstract][Full Text] [Related]
12. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
13. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
[TBL] [Abstract][Full Text] [Related]
14. Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.
Costa L; Lubrano E; Ramonda R; Chimenti MS; Vezzù M; Perrotta FM; Del Puente A; Peluso R; Bottiglieri P; Lorenzin M; Sunzini F; Darda MA; Fiocco U; Perricone R; Punzi L; Scarpa R; Caso F
Clin Rheumatol; 2017 Aug; 36(8):1797-1802. PubMed ID: 28589323
[TBL] [Abstract][Full Text] [Related]
15. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
16. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
17. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
[TBL] [Abstract][Full Text] [Related]
18. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
[TBL] [Abstract][Full Text] [Related]
19. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
[TBL] [Abstract][Full Text] [Related]
20. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
